Efficient Delivery of Therapeutic SiRNA by FeO Magnetic Nanoparticles into Oral Cancer Cells

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2019 Nov 21

PMID 31744202

Citations 37

Authors

Lili Jin

Qiuyu Wang

Jiayu Chen

Zixiang Wang

Hongchuan Xin

Dianbao Zhang

Affiliations

Soon will be listed here.

Abstract

The incidence of oral cancer is increasing due to smoking, drinking, and human papillomavirus (HPV) infection, while the current treatments are not satisfactory. Small interfering RNA (siRNA)-based therapy has brought hope, but an efficient delivery system is still needed. Here, polyethyleneimine (PEI)-modified magnetic FeO nanoparticles were prepared for the delivery of therapeutic siRNAs targeting B-cell lymphoma-2 (BCL2) and Baculoviral IAP repeat-containing 5 (BIRC5) into Ca9-22 oral cancer cells. The cationic nanoparticles were characterized by transmission electronic microscopy (TEM), scanning electronic microscopy (SEM), dynamic light scattering (DLS), and vibrating sample magnetometer (VSM). By gel retardation assay, the nanoparticles were found to block siRNA in a concentration-dependent manner. The cellular uptake of the nanoparticle/siRNA complexes under a magnetic field was visualized by Perl's Prussian blue staining and FAM labeling. High gene silencing efficiencies were determined by quantitative real-time PCR and western blotting. Furthermore, the nanoparticle-delivered siRNAs targeting BCL2 and BIRC5 were found to remarkably inhibit the viability and migration of Ca9-22 cells, by cell counting kit-8 assay and transwell assay. In this study, we have developed a novel siRNA-based therapeutic strategy targeting BCL2 and BIRC5 for oral cancer.

Citing Articles

Recent Advancements in Nanopharmaceuticals for Novel Drug Delivery Systems.

Liew K, Koh E, Kong X, Ismail N, Abu Bakar R, Kee P Pharm Nanotechnol. 2024; 13(2):271-286.

PMID: 39323341 DOI: 10.2174/0122117385324246240826042254.

Green Dentistry in Oral Cancer Treatment Using Biosynthesis Superparamagnetic Iron Oxide Nanoparticles: A Systematic Review.

Reviansyah F, Putra D, Supriatna J, Takarini V, Komariah M Cancer Manag Res. 2024; 16:1231-1245.

PMID: 39282609 PMC: 11402364. DOI: 10.2147/CMAR.S477791.

Nanoparticle-based immunosensors for enhanced DNA analysis in oral cancer: A systematic review.

Gupta N, Bhargava A, Saigal S, Mehta V J Oral Maxillofac Pathol. 2024; 28(2):284-292.

PMID: 39157838 PMC: 11329074. DOI: 10.4103/jomfp.jomfp_345_23.

Co-delivery of Siape1 and Melatonin by I-loaded PSMA-targeted Nanoparticles for the Treatment of Prostate Cancer.

Liu Y, Hao L, Dong Y, Dong B, Wang X, Liu X Recent Pat Anticancer Drug Discov. 2024; 19(4):503-515.

PMID: 39044710 PMC: 11348473. DOI: 10.2174/1574892818666230419081414.

Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives.

Rehan F, Zhang M, Fang J, Greish K Molecules. 2024; 29(9).

PMID: 38731563 PMC: 11085487. DOI: 10.3390/molecules29092073.

References

Reynolds A, Leake D, Boese Q, Scaringe S, Marshall W, Khvorova A . Rational siRNA design for RNA interference. Nat Biotechnol. 2004; 22(3):326-30. DOI: 10.1038/nbt936. View

Li C, Shen Z, Bavarian R, Yang F, Bhattacharya A . Oral Cancer: Genetics and the Role of Precision Medicine. Dent Clin North Am. 2017; 62(1):29-46. DOI: 10.1016/j.cden.2017.08.002. View

Delbridge A, Grabow S, Strasser A, Vaux D . Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016; 16(2):99-109. DOI: 10.1038/nrc.2015.17. View

Bochicchio S, Dapas B, Russo I, Ciacci C, Piazza O, De Smedt S . In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer. Int J Pharm. 2017; 525(2):377-387. DOI: 10.1016/j.ijpharm.2017.02.020. View

Maheshwari R, Tekade M, Gondaliya P, Kalia K, DEmanuele A, Kumar Tekade R . Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers. Nanomedicine (Lond). 2017; 12(21):2653-2675. DOI: 10.2217/nnm-2017-0210. View

Dong Y, Siegwart D, Anderson D . Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019; 144:133-147. PMC: 6745264. DOI: 10.1016/j.addr.2019.05.004. View

Setten R, Rossi J, Han S . The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019; 18(6):421-446. DOI: 10.1038/s41573-019-0017-4. View

Cheraghlou S, Schettino A, Zogg C, Judson B . Changing prognosis of oral cancer: An analysis of survival and treatment between 1973 and 2014. Laryngoscope. 2018; 128(12):2762-2769. DOI: 10.1002/lary.27315. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Calatayud M, Riggio C, Raffa V, Sanz B, Torres T, Ibarra M . Neuronal cells loaded with PEI-coated FeO nanoparticles for magnetically guided nerve regeneration. J Mater Chem B. 2020; 1(29):3607-3616. DOI: 10.1039/c3tb20336k. View

11.

Martinez-Garcia D, Manero-Ruperez N, Quesada R, Korrodi-Gregorio L, Soto-Cerrato V . Therapeutic strategies involving survivin inhibition in cancer. Med Res Rev. 2018; 39(3):887-909. DOI: 10.1002/med.21547. View

12.

Marcazzan S, Varoni E, Blanco E, Lodi G, Ferrari M . Nanomedicine, an emerging therapeutic strategy for oral cancer therapy. Oral Oncol. 2018; 76:1-7. DOI: 10.1016/j.oraloncology.2017.11.014. View

13.

Denais C, Gilbert R, Isermann P, McGregor A, Te Lindert M, Weigelin B . Nuclear envelope rupture and repair during cancer cell migration. Science. 2016; 352(6283):353-8. PMC: 4833568. DOI: 10.1126/science.aad7297. View

14.

Knight T, Luedtke D, Edwards H, Taub J, Ge Y . A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol. 2019; 162:250-261. DOI: 10.1016/j.bcp.2019.01.015. View

15.

Radha G, Raghavan S . BCL2: A promising cancer therapeutic target. Biochim Biophys Acta Rev Cancer. 2017; 1868(1):309-314. DOI: 10.1016/j.bbcan.2017.06.004. View

16.

Selvam C, Mutisya D, Prakash S, Ranganna K, Thilagavathi R . Therapeutic potential of chemically modified siRNA: Recent trends. Chem Biol Drug Des. 2017; 90(5):665-678. PMC: 5935465. DOI: 10.1111/cbdd.12993. View

17.

Ma C, Shi L, Huang Y, Shen L, Peng H, Zhu X . Nanoparticle delivery of Wnt-1 siRNA enhances photodynamic therapy by inhibiting epithelial-mesenchymal transition for oral cancer. Biomater Sci. 2017; 5(3):494-501. DOI: 10.1039/c6bm00833j. View

18.

Xiong L, Tang Y, Liu Z, Dai J, Wang X . BCL-2 inhibition impairs mitochondrial function and targets oral tongue squamous cell carcinoma. Springerplus. 2016; 5(1):1626. PMC: 5031576. DOI: 10.1186/s40064-016-3310-2. View

19.

Gomes-da-Silva L, Fonseca N, Moura V, de Lima M, Simoes S, Moreira J . Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res. 2012; 45(7):1163-71. DOI: 10.1021/ar300048p. View

20.

Troiano G, Guida A, Aquino G, Botti G, Losito N, Papagerakis S . Integrative Histologic and Bioinformatics Analysis of BIRC5/Survivin Expression in Oral Squamous Cell Carcinoma. Int J Mol Sci. 2018; 19(9). PMC: 6174346. DOI: 10.3390/ijms19092664. View